Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Adma Biologics (ADMA) stock in plain English

Free brief · no signupStart here
ADMAPublished Nov 12, 2026
Adma Biologics Inc
Healthcare · Biotechnology
Manufactures specialized plasma-derived biologics to treat patients with immunodeficiencies and infectious disease risks.
Assets:
Boca Raton FacilityPlasma fractionation plant located in Florida
ASCENIV TherapyPatented hyperimmune globulin for primary immunodeficiency
ADMA BioCentersNetwork of donor plasma collection centers in the United States
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

88
OPS ScoreOperating finances
Latest quote
-1.62%$13.34
$2.96B
17.2×
$519.22M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ADMA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Adma Biologics (ADMA) do?

Adma Biologics Inc (ADMA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures specialized plasma-derived biologics to treat patients with immunodeficiencies and infectious disease risks. It collects human plasma and fractionates specialty hyperimmune treatments through its own vertically integrated. It is worth $2.96B on the market and sold $519.22M over the last year.

Market cap
$2.96B
P/E ratio
17.2×
Annual sales
$519.22M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 12, 2026

Brands and businesses behind ADMA

  • ASCENIV: It is a patented intravenous hyperimmune therapy that generates revenue from sales to treat immune-deficient patients.
  • BIVIGAM: It is an intravenous immune globulin therapy sold to specialty distributors for patients with primary humoral immunodeficiency.
  • Nabi-HB: It is a specialized hepatitis B immune globulin treatment sold to prevent infection following acute exposure.

ADMA’s flags, in plain English

Each flag is a number from Adma Biologics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Stupid Cash

Can pay this year's bills 6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Fat Margins

Profit margin of 35.1%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Earns Its Keep

Earns 42% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Worth a Look

Hospital distributor payment delays slow down cash collection on delivered immune globulin therapies. Something here could change the picture, so it is worth reading next to the good news.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about ADMA

How big is Adma Biologics?

Adma Biologics’ market cap is $2.96B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $519.22M: what customers paid the company over the last year, before any costs.

What is ADMA’s P/E ratio?

ADMA’s P/E ratio is 17.2×. Investors pay about 17.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ADMA?

The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Adma Biologics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ADMA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card